Dyne Stock Gains 10% on Initiation of Late-Stage Study in DMD Patients
Dyne Therapeutics' shares rose 10% after the company announced the initiation of its phase III FORZETTO study for zeleciment rostudirsen (z-rostudirsen/DYNE-251) in ambulatory male patients with Duchenne muscular dystrophy (DMD). This late-stage study aims to evaluate the safety and efficacy of the treatment, building on prior positive results from the phase I/II DELIVER study, which has supported potential accelerated approval pathways with the FDA. In addition to z-rostudirsen, Dyne is also advancing other preclinical DMD programs.
Dyne spikes as late-stage trial for Duchenne therapy gets underway
Dyne Therapeutics' stock surged after the initiation of a global late-stage clinical trial for its Duchenne muscular dystrophy (DMD) therapy, DYNE-251. The trial will evaluate the drug's safety and efficacy in patients with amenable mutations. This advancement follows positive early-stage trial data and could offer a significant treatment option for the severe genetic disorder.
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dyne Therapeutics (Nasdaq: DYN) announced it has granted inducement equity awards to 17 new employees, as per Nasdaq Listing Rule 5635(c)(4). These awards include non-statutory stock options for 296,500 shares and restricted stock units for 94,100 shares, both vesting over four years. The grants serve as an inducement for their acceptance of employment.
DYN: 2026 targets commercial launches for DMD and DM1, with pipeline expansion and strong clinical data
Dyne Therapeutics (DYN) aims for commercial launches of treatments for Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy Type 1 (DM1) in 2026. This initiative is supported by strong clinical data and a de-risked platform. The company also plans to expand its pipeline into additional exons and FSHD, focusing on capital-efficient development and competitive differentiation.
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy Ahead of Planned BLA Submission for U.S. Accelerated Approval
Dyne Therapeutics has initiated the Phase 3 FORZETTO trial for z-rostudirsen in Duchenne muscular dystrophy (DMD) patients amenable to exon 51 skipping. This global, randomized, placebo-controlled study will enroll approximately 90 participants aged 4 to 18 to evaluate efficacy, safety, and tolerability, with its design aligned with the FDA. The trial is intended as a confirmatory study for potential traditional approval in the U.S. and to support ex-U.S. marketing applications, following promising results from the Phase 1/2 DELIVER trial that will support a U.S. Accelerated Approval submission later this quarter.
Dyne Therapeutics launches phase 3 trial for DMD treatment
Dyne Therapeutics has initiated its Phase 3 FORZETTO trial for zeleciment rostudirsen, a treatment for Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. This 72-week trial aims to enroll approximately 90 ambulatory male participants aged 4 to 18 years, serving as a confirmatory study for potential Accelerated Approval conversion in the U.S. Despite a recent stock decline, analysts remain optimistic, with several firms reiterating positive ratings and price targets based on the company's clinical and regulatory progress.
Dyne Therapeutics Stock Rises 40% in a Year, but Saturn V Fund Reduces Holdings
Dyne Therapeutics stock has seen a nearly 40% increase over the past year, outperforming the S&P 500. However, Saturn V Capital Management, a biotechnology-focused fund, reduced its stake in Dyne by $14.17 million in the first quarter, although it still holds nearly 1 million shares. This reduction comes as Dyne Therapeutics makes progress with its investigational drug z-rostudirsen and maintains a substantial cash reserve, even as its net losses widen.
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares
Saturn V Capital Management LP recently disclosed selling 822,007 shares of Dyne Therapeutics for an estimated $14.17 million. Despite the sale, Dyne Therapeutics shares have risen nearly 40% over the past year. The fund still holds nearly a million shares, suggesting the sale might be a trimming of exposure ahead of regulatory catalysts, as Dyne Therapeutics progresses with its investigational drug for muscular dystrophy and maintains a strong cash position.
Assessing Dyne Therapeutics (DYN) Valuation After Recent Pullback And Contrasting P/B And DCF Signals
Dyne Therapeutics (DYN) has experienced a recent pullback, with its stock closing at $17.29, despite strong longer-term returns. The company is in clinical stages, operating at a net loss, and its valuation presents conflicting signals: a P/B ratio of 3.3x suggests it's valued above the industry average but below peers, while a Discounted Cash Flow (DCF) model indicates a fair value of $105.60. Investors are encouraged to assess both risk factors and potential rewards before making a decision.
Janus Henderson reports 13.65M shares in Dyne Therapeutics (NASDAQ: DYN)
Janus Henderson Group plc has reported beneficial ownership of 13,647,376 shares of Dyne Therapeutics (NASDAQ: DYN) common stock, representing an 8.3% stake in the company. This ownership is held within Managed Portfolios of their affiliated investment advisers, meaning Janus Henderson exercises shared voting and shared dispositive power but the client portfolios retain rights to dividends and sale proceeds. The filing clarifies that this is a passive investment, not intended for changing or influencing control of the issuer.
T. Rowe Price (NASDAQ: DYN) holds 30.8M shares, a 18.7% stake
T. Rowe Price Investment Management, Inc. has amended its Schedule 13G filing to report a beneficial ownership of 30,785,801 shares of Dyne Therapeutics common stock, representing an 18.7% stake as of March 31, 2026. The filing indicates sole voting power over 30,419,012 shares and was signed by Ellen York, Vice President, on May 15, 2026. Despite the substantial stake, the filing includes a statement denying beneficial ownership, indicating a passive investment intent.
Dyne Therapeutics (NASDAQ:DYN) Insider Sells $28,715.04 in Stock
Dyne Therapeutics (NASDAQ:DYN) insider Douglas Kerr recently sold 1,564 shares of the company's stock, valued at $28,715.04, to cover tax withholding obligations associated with vested equity awards. Following the sale, Kerr directly owns 170,042 shares. The company's stock traded down 0.9% to $18.28 after the announcement, despite beating recent quarterly earnings estimates, and analysts maintain a "Moderate Buy" consensus rating with an average price target of $35.21.
Dyne Therapeutics (NASDAQ:DYN) CEO John Cox Sells 3,311 Shares
Dyne Therapeutics CEO John Cox sold 3,311 shares of the company's stock for approximately $60,790 to cover tax withholding obligations related to equity awards. Despite this sale, Cox's direct ownership remains substantial at over 370,000 shares. The company recently reported a narrower quarterly loss than expected, and analysts maintain a "Moderate Buy" rating with a target price of $35.21, though some long-term earnings forecasts have been trimmed.
[Form 4] Dyne Therapeutics, Inc. Insider Trading Activity
Dyne Therapeutics, Inc.'s Chief Medical Officer, Douglas Kerr, reported an automatic sale of 1,564 shares of common stock on May 13, 2026, at a weighted average price of $18.36 per share. This sale was conducted to satisfy tax withholding obligations related to the vesting of restricted stock units and was pre-planned under a Rule 10b5-1 agreement. Following the transaction, Kerr directly holds 170,042 shares, including 148,313 unvested restricted stock units.
Dyne therapeutics CFO Lucera sells $26,585 in company stock
Erick Lucera, CFO of Dyne Therapeutics, sold 1,448 shares for $26,585 to cover tax withholding obligations from vesting restricted stock units. This was an automatic, non-discretionary transaction. Following the sale, Lucera still holds 123,925 shares, including unvested RSUs. The report also highlights recent analyst coverage, with multiple firms maintaining "Buy" or "Outperform" ratings for Dyne Therapeutics based on positive clinical progress and regulatory environment.
Dyne Therapeutics (DYN) CFO logs automatic 1,448-share tax-related sale
Dyne Therapeutics (DYN) CFO Erick Lucera automatically sold 1,448 shares at a weighted average price of $18.36 to cover tax withholding obligations from vested restricted stock units. This was a pre-arranged, non-discretionary transaction under a Rule 10b5-1 plan. Following the sale, Lucera directly holds 123,925 shares, including 110,513 unvested restricted stock units, indicating a substantial ongoing equity interest in the company.
Dyne Therapeutics (DYN) CCO auto-sells shares to cover RSU taxes
Dyne Therapeutics' Chief Commercial Officer, Johanna Friedl-Naderer, automatically sold 228 shares of common stock at a weighted average price of $18.36 per share on May 13, 2026. This sale was a pre-arranged transaction under Rule 10b5-1 to cover tax withholding obligations from vesting restricted stock units and was not a discretionary trade. After the transaction, she still holds 154,353 shares, including 126,040 unvested restricted stock units.
Dyne Therapeutics to Participate in Upcoming Investor Conferences
Dyne Therapeutics (Nasdaq: DYN), a clinical-stage company focusing on neuromuscular diseases, announced its participation in several upcoming investor conferences in May and June 2026. The company will hold fireside chats at the RBC Capital Markets Global Healthcare Conference and the Jefferies Global Healthcare Conference, and host meetings at the Goldman Sachs 47th Annual Global Healthcare Conference. Webcasts of the fireside chats will be available on Dyne's investor relations website.
Form 144 filed on restricted stock units for DYN (NASDAQ: DYN)
A Form 144 was filed for Dyne Therapeutics (NASDAQ: DYN) regarding the proposed sale of 11,250 Restricted Stock Units and disclosing a prior disposition of 2,732 shares on March 5, 2026. The filing indicates 165,313,769 shares outstanding as of May 13, 2026, and is considered neutral in impact and sentiment. This procedural notice provides details on securities offered under equity compensation but does not specify sale prices or cash-flow treatment.
DYN (Nasdaq) insider resale of 5,727 shares; 4,062 RSUs granted
Dyne Therapeutics (DYN) filed a Rule 144 notice detailing a restricted-stock issuance and an insider resale. The filing reports that 4,062 Restricted Stock Units were granted on May 12, 2026, and Erick Lucera resold 5,727 shares on April 1, 2026. The company had 165,313,796 shares outstanding as of May 13, 2026.
Dyne Therapeutics to Participate in Upcoming Investor Conferences
Dyne Therapeutics, Inc. announced its participation in several upcoming investor conferences in May and June 2026. The company's management is scheduled to participate in fireside chats at the 2026 RBC Capital Markets Global Healthcare Conference and the 2026 Jefferies Global Healthcare Conference, and will host meetings at the Goldman Sachs 47th Annual Global Healthcare Conference 2026. Dyne Therapeutics is a clinical-stage company focusing on developing treatments for genetically driven neuromuscular diseases.
Clinical-stage Dyne Therapeutics lines up three healthcare investor events
Dyne Therapeutics (Nasdaq: DYN) has announced its participation in three upcoming healthcare investor conferences in May and June 2026. Management will host fireside chats at the RBC Capital Markets Global Healthcare Conference and the Jefferies Global Healthcare Conference, and investor meetings at the Goldman Sachs 47th Annual Global Healthcare Conference. Live webcasts and replays of the fireside chats will be available on the company's website.
Dyne Therapeutics to Participate in Upcoming Investor Conferences
Dyne Therapeutics, Inc. announced its participation in several upcoming investor conferences, including fireside chats at the 2026 RBC Capital Markets Global Healthcare Conference and the 2026 Jefferies Global Healthcare Conference, and meetings at the Goldman Sachs 47th Annual Global Healthcare Conference 2026. The company, focused on genetically driven neuromuscular diseases, will provide a live webcast and replay of the fireside chats for investors.
Dyne Therapeutics | 10-Q: Q1 2026 Earnings Report
This article provides the Q1 2026 earnings report for Dyne Therapeutics in the form of a 10-Q document. It contains the complete regulatory filing detailing the company's financial performance for the quarter.
Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
Dyne Therapeutics announced its Q1 2026 financial results, highlighting significant progress in its Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) programs. The company completed a positive pre-BLA meeting with the FDA for z-rostudirsen in exon 51 DMD, with a BLA submission expected in Q2 2026 and a potential launch in Q1 2027. Dyne also initiated a global confirmatory Phase 3 trial for z-basivarsen in DM1 and presented new preclinical data demonstrating the blood-brain barrier crossing capabilities of its FORCE™ platform.
Dyne Therapeutics 1Q 2026: Net loss $(120.9M), EPS $(0.73) — 10-Q Summary
Dyne Therapeutics reported a net loss of $(120.9M) for the first quarter of 2026, a slight increase from $(115.4M) in the prior year, though diluted EPS improved to $(0.73) from $(1.05) due to a higher share count. The company highlighted ongoing clinical trials, including its DELIVER (DMD) Phase 1/2 study with a BLA planned for Q2 2026, and the initiation of the Phase 3 HARMONIA trial for DM1. Operational growth involved increased manufacturing and workforce expansion to support pipeline advancement and launch preparations.
Dyne Therapeutics (DYN) Upgraded to Buy: Here's What You Should Know
Dyne Therapeutics (DYN) has received an upgrade to a Zacks Rank #2 (Buy) due to an upward trend in its earnings estimates. This upgrade suggests a positive outlook for the company's earnings, which historically correlates with favorable stock price movements. The Zacks Rank system, which measures earnings estimate revisions, has a strong track record of identifying stocks that outperform the market.
Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
Dyne Therapeutics has released its first quarter 2026 financial results and provided updates on its clinical programs. The company plans to submit a BLA for z-rostudirsen in DMD in Q2 2026, aiming for a Q1 2027 launch, and has initiated a Phase 3 trial for z-basivarsen in DM1 with data expected in Q1 2027. Dyne also presented new preclinical data on its FORCE platform demonstrating blood-brain barrier penetration, and reported a net loss of $120.9 million for the quarter.
Press Release: Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
Dyne Therapeutics reported its first-quarter 2026 financial results, highlighting progress in its clinical programs and financial position. The company is advancing multiple drug candidates for muscle diseases, with an emphasis on its ACHIEVE and DELIVER trials. The financial results will be discussed in detail during an upcoming conference call.
Dyne Therapeutics Releases Q1 2026 Financial Results
Dyne Therapeutics, Inc. (DYN) reported a narrower net loss of $120.9 million, or $0.73 per share, for the first quarter of 2026, showing a 30.5% improvement year-over-year. This positive development reflects the clinical-stage biotechnology company's progress in advancing its therapeutic pipeline for neuromuscular diseases. Wall Street analysts maintain a positive outlook with 10 buy and 3 hold ratings, indicating confidence in the company's research and future commercialization potential.
Earnings Flash (DYN) Dyne Therapeutics Posts Q1 Loss $0.73 a Share, vs. FactSet Est of $0.74 Loss
Dyne Therapeutics (DYN) reported a Q1 loss of $0.73 per share, which is lower than FactSet's estimated loss of $0.74 per share. The company is a clinical-stage neuromuscular disease firm developing targeted therapeutics for genetically driven conditions. Its pipeline includes programs for myotonic dystrophy type 1 and Duchenne muscular dystrophy.
Dyne Therapeutics (NASDAQ: DYN) details DMD and DM1 trial progress
Dyne Therapeutics reported its Q1 2026 financial results, including a net loss of $120.9 million, and provided significant updates on its Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) programs. The company expects its $972.2 million cash reserves to fund operations into Q1 2028. Key clinical progress includes a positive pre-BLA meeting for z-rostudirsen in DMD, with a BLA submission planned for Q2 2026, and the completion of enrollment in the registrational expansion cohort for z-basivarsen in DM1, with data expected in Q1 2027.
Dyne Therapeutics Q1 Net Loss Widens
Dyne Therapeutics, Inc. reported a wider net loss for the first quarter of $120.85 million, or $0.73 per share, compared to $115.36 million, or $1.05 per share, in the prior-year quarter. Following the announcement, DYN shares were trading down 0.62 percent at $17.50 in pre-market trading on the Nasdaq.
Number of shareholders of Dyne Therapeutics, Inc. – NASDAQ:DYN
This article provides details on the number of shareholders for Dyne Therapeutics, Inc. (NASDAQ: DYN). It is a brief financial snippet from TradingView, offering a snapshot of a specific period's value and percentage change relating to the number of shareholders.
Dyne Therapeutics (DYN) Q1 2026 results: $972M cash position
Dyne Therapeutics (DYN) reported a $972.2 million cash position at the end of Q1 2026, providing a financial runway into Q1 2028. The company is set to submit a Biologics License Application (BLA) for z-rostudirsen in Duchenne muscular dystrophy (DMD) in Q2 2026, targeting a Q1 2027 commercial launch. Additionally, its myotonic dystrophy type 1 (DM1) program, z-basivarsen, has entered Phase 3 trials with a potential market entry in early 2028.
A Look At Dyne Therapeutics (DYN) Valuation After New CNS Tauopathy Data And Pipeline Expansion Potential
Dyne Therapeutics recently released new preclinical data for its FORCE platform, demonstrating MAPT RNA knockdown in the central nervous system, broadening its potential pipeline to include tauopathy applications like Alzheimer's. While the company's valuation presents mixed signals, trading at a 3x Price-to-Book ratio (a premium to the broader US Biotechs industry but a discount to its specific peer group), a Discounted Cash Flow model suggests the stock is heavily undervalued. Investors are encouraged to assess the balance of upside and downside, considering the potential risks and rewards of Dyne's pipeline expansion.
[144] Dyne Therapeutics, Inc. SEC Filing
This article details a Form 144 SEC filing by Dyne Therapeutics, Inc. (DYN) on May 6, 2026, indicating a proposed sale of 43,621 common shares with an aggregate market value of $762,058.87. The shares were acquired through a private placement in July 2020. The filing also provides an overview of recent news and SEC filings for Dyne Therapeutics, highlighting various corporate updates and other regulatory documents.
Dyne Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
This article is a notice of a proposed sale of securities for Dyne Therapeutics, pursuant to Rule 144. It indicates a formal declaration regarding upcoming stock transactions. The content itself is just the word "Document", suggesting the full details are in an attached or linked document.
Dyne Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
This document is a formal Notice of Proposed Sale of Securities pursuant to Rule 144 for Dyne Therapeutics. Such notices indicate an intent to sell restricted or control securities under specific conditions set forth by the SEC. This filing provides transparency regarding potential insider or affiliated person stock sales.
[144] Dyne Therapeutics, Inc. SEC Filing
This article details a Form 144 SEC filing by Dyne Therapeutics, Inc. (DYN) on May 6, 2026. The filing indicates a neutrality in both its impact and sentiment and concerns a proposed sale of 17,244 shares of common stock with an aggregate market value of $301,252.68. The shares were acquired via private placement in August 2020 and are intended to be sold on the Nasdaq through Merrill Lynch.
Dyne therapeutics director Jason Rhodes sells $1.9m in shares
Jason P. Rhodes, a director at Dyne Therapeutics, Inc., sold 106,723 shares of common stock for over $1.9 million between May 4-6, 2026, through indirect holdings in Atlas Venture funds. Despite these sales, the company maintains a strong financial position with significant cash and high liquidity, and analysts largely hold a bullish outlook with price targets up to $50. Dyne Therapeutics has also seen positive affirmations from several analyst firms following clinical advancements in its Duchenne muscular dystrophy and myotonic dystrophy programs.
Atlas funds trim Dyne Therapeutics (DYN) stake in planned stock sales
Funds managed by Atlas Venture, associated with Dyne Therapeutics director Jason P. Rhodes, sold 106,723 shares of Dyne Therapeutics (DYN) common stock between May 4-6, 2026. These sales, conducted at weighted average prices around $18.00-$18.18 per share, were made pursuant to a Rule 10b5-1 trading plan. Despite these transactions, the Atlas Venture entities still maintain multi-million-share positions in Dyne.
Dyne Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
This article is a Rule 144 notice of proposed sale of securities for Dyne Therapeutics. It indicates that documents related to this notice are available, likely detailing the specifics of the securities sale.
DYN SEC Filings - Dyne Therapeutics, Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Dyne Therapeutics (DYN) SEC filings, including annual reports (10-K), quarterly earnings (10-Q), material events (8-K), and insider trading forms. It highlights how Stock Titan integrates AI-powered summaries to help investors quickly parse key information from these documents. The article also lists recent filings and provides company information such as market cap and industry.
FMR LLC reports 5.4% stake in Dyne Therapeutics (NASDAQ: DYN) in Schedule 13G
FMR LLC has reported a 5.4% beneficial ownership stake in Dyne Therapeutics (NASDAQ: DYN) through a Schedule 13G filing. As of March 31, 2026, FMR LLC holds 8,908,979.89 shares, with sole voting power over 8,900,472 shares and sole dispositive power over all owned shares. This filing indicates a passive investment, as Schedule 13G is used for substantial holdings by investment managers rather than activist intent.
Dyne Therapeutics (Nasdaq:DYN) - Stock Analysis
Dyne Therapeutics (NASDAQ: DYN) is a clinical-stage biotech company focused on neuromuscular diseases, with a current market cap of US$3.1 billion. The stock is considered significantly undervalued, trading at a substantial discount to its estimated fair value. Dyne recently announced positive preclinical data for its FORCE platform to cross the blood-brain barrier and positive long-term cardiopulmonary results from its DELIVER trial for Duchenne muscular dystrophy, reinforcing its pipeline progress despite risks like shareholder dilution and unprofitability.
[144] Dyne Therapeutics, Inc. SEC Filing
Dyne Therapeutics, Inc. (DYN) filed a Form 144 with the SEC on May 5, 2026, indicating a proposed sale of 60 shares of common stock acquired through a private placement on April 26, 2019. The shares have an aggregate market value of $1062.6 and are to be sold on the Nasdaq exchange through Merrill Lynch. The filing also states that the filer does not know of any material adverse information regarding the issuer.
[144] Dyne Therapeutics, Inc. SEC Filing
Dyne Therapeutics, Inc. has filed a Form 144 with the SEC, indicating a proposed sale of securities. The filing details include the sale of 61 shares of common stock with an aggregate market value of $1060.79 to be sold through Merrill Lynch on the Nasdaq exchange. The securities were acquired through a private placement from the Issuer on April 26, 2019.
Wall Street Zen Downgrades Dyne Therapeutics (NASDAQ:DYN) to Strong Sell
Wall Street Zen has downgraded Dyne Therapeutics (NASDAQ:DYN) from "sell" to "strong sell," despite other analysts maintaining a "Moderate Buy" consensus with a price target of $35.14. Insiders have been net sellers, offloading approximately $27.8 million worth of shares in the last 90 days, though one director recently purchased 3,000 shares. The company recently missed its EPS estimates and has a current market capitalization of $2.87 billion.
Insider Selling: Dyne Therapeutics (NASDAQ:DYN) Director Sells 227,337 Shares of Stock
Dyne Therapeutics (NASDAQ:DYN) Director Jason Rhodes sold 227,337 shares of the company's stock on April 28th at an average price of $18.38, totaling over $4.17 million. This transaction, executed under a pre-arranged Rule 10b5-1 trading plan, significantly reduced his stake by 96.39% to 8,511 shares. The company has a consensus "Moderate Buy" rating and a target price of $35.14 from analysts, while its stock currently trades around $17.55 with a market cap of $2.90 billion.
